ENVB vs LSCC vs AMAT vs CMPS vs MNMD

For growth investors, Applied Materials, Inc.

(AMAT) is the stronger pick with 4. 4% revenue growth year-over-year, versus 2. 7% for Lattice Semiconductor Corporation (LSCC). Applied Materials, Inc. (AMAT) offers the better valuation at 50. 3x trailing P/E (39. 3x forward), making it the more compelling value choice. Analysts rate Lattice Semiconductor Corporation (LSCC) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Applied Materials, Inc.

(AMAT) is the cheapest at 50. 3x versus Lattice Semiconductor Corporation at 5703. 6x. On forward P/E, Applied Materials, Inc. is actually cheaper at 39. 3x.

Over the past 5 years, Applied Materials, Inc.

(AMAT) delivered a total return of +254. 5%, compared to -100. 0% for Enveric Biosciences, Inc. (ENVB). Over 10 years, the gap is even starker: LSCC returned +23. 5% versus ENVB's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.

28β versus Lattice Semiconductor Corporation's 2. 40β — meaning LSCC is approximately 88% more volatile than CMPS relative to the S&P 500. On balance sheet safety, Lattice Semiconductor Corporation (LSCC) carries a lower debt/equity ratio of 11% versus 32% for Applied Materials, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Applied Materials, Inc.

(AMAT) is pulling ahead at 4. 4% versus 2. 7% for Lattice Semiconductor Corporation (LSCC). On earnings-per-share growth, the picture is similar: Applied Materials, Inc. grew EPS 0. 6% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, AMAT leads at 3. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Applied Materials, Inc.

(AMAT) is the more profitable company, earning 24. 7% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 24. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMAT leads at 29. 2% versus 0. 0% for MNMD. At the gross margin level — before operating expenses — LSCC leads at 68. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Applied Materials, Inc.

(AMAT) trades at 39. 3x forward P/E versus 121. 1x for Lattice Semiconductor Corporation — 81. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CMPS: 81. 6% to $18. 00.

In this comparison, AMAT (0.

4% yield) pays a dividend. ENVB, LSCC, CMPS, MNMD do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mind Medicine (MindMed) Inc.

(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Applied Materials, Inc. (AMAT) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, AMAT: +21. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ENVB (Healthcare) and LSCC (Technology) and AMAT (Technology) and CMPS (Healthcare) and MNMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.